RevealDx, a pioneer in AI driven lung imaging, has entered a distribution agreement with 4DMedical to bring its RevealAI Lung technology to markets in the US, Europe, Australia, and New Zealand. The deal includes a strategic investment from 4DMedical, strengthening RevealDx's position in the medical imaging sector. This collaboration aims to enhance early detection and characterization of lung diseases using advanced artificial intelligence.
RevealDx, a company specializing in AI powered lung imaging, has announced a distribution agreement with 4DMedical, a global leader in respiratory imaging technology. Under the terms of the deal, 4DMedical will distribute RevealDx's RevealAI Lung platform across key markets, including the United States, Europe, Australia, and New Zealand. The agreement also includes a strategic investment from 4DMedical, further solidifying the partnership.
RevealAI Lung leverages artificial intelligence to analyze lung imaging data, providing clinicians with detailed insights into lung tissue characterization. This technology is designed to improve the early detection and diagnosis of lung diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer. The platform integrates seamlessly with existing imaging workflows, offering a non invasive and efficient solution for healthcare providers.
DISCUSSION (0)